CWA
CLDX icon

CM Wealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

CM Wealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,590
Closed -$245K – 217
2023
Q1 		$245K Buy
+7,590
New +$328K 0.05% 347

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

CM Wealth Advisors's CLDX Position: Q2 2023 in Review

CM Wealth Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 7,590 shares — an estimated $245K sold.

CM Wealth Advisors first reported a position in CLDX in Q1 2023 and held it in 1 quarter. The position peaked at $245K in Q1 2023. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • CM Wealth Advisors reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CM Wealth Advisors sold 7,590 Celldex Therapeutics shares in Q2 2023, an estimated $245K.
  • CM Wealth Advisors first reported a position in Celldex Therapeutics in Q1 2023 and held it in 1 quarter.
  • CM Wealth Advisors's Celldex Therapeutics position peaked at $245K in Q1 2023.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on CM Wealth Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.